MedTrace Logo

IMUNOR® Preparation in the Prevention of COVID-19

NCT04710381 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2021-07-21

No results posted yet for this study

Summary

The aim of the study is to achieve prevention of COVID-19 disease in healthcare professionals with the administration of the IMUNOR® preparation, and decreasing the symptoms should the disease appear.

Conditions

  • Covid19

Interventions

DRUG

IMUNOR

The intervention consists of the administration of IMUNOR as prevention against COVID-19 disease

Sponsors & Collaborators

  • University Hospital Ostrava

    lead OTHER

Principal Investigators

  • Jaromír Bystroň, Ass.Prof.,MD,CSc. · University Hospital Ostrava

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2021-06-02
Completion
2021-06-02

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04710381 on ClinicalTrials.gov